Full metadata record
DC FieldValueLanguage
dc.contributor.authorHatzimichael, Eleftheria-
dc.contributor.authorLagos, Konstantinos-
dc.contributor.authorSim, Van Ren-
dc.contributor.authorBriasoulis, Evangelos-
dc.contributor.authorCrook, Tim-
dc.date.accessioned2014-11-27T13:00:10Z-
dc.date.available2014-11-27T13:00:10Z-
dc.date.issued2014-08-26-
dc.identifier.issn1611-2156-
dc.identifier.urihttp://hdl.handle.net/2003/33742-
dc.identifier.urihttp://dx.doi.org/10.17877/DE290R-6936-
dc.description.abstractCancer cells contain multiple genetic and epigenetic changes. The relative specificity of many epigenetic changes for neoplastic cells has allowed the identification of diagnostic, prognostic and predictive biomarkers for a number of solid tumors and hematological malignancies. Moreover, epigenetically-acting drugs are already in routine use for cancer and numerous additional agents are in clinical trials. Here, we review recent progress in the development and application of epigenetic strategies for the diagnosis, risk stratification and treatment of cancer.en
dc.language.isoen-
dc.relation.ispartofseriesEXCLI Journal ; Vol. 13, 2014en
dc.subjectepigeneticsen
dc.subjectmethylationen
dc.subjectacetylationen
dc.subjectdiagnosisen
dc.subjecttreatmenten
dc.subjectcanceren
dc.subjecthematological malignanciesen
dc.subjecthypomethylating agentsen
dc.subject.ddc610-
dc.titleEpigenetics in diagnosis, prognostic assessment and treatment of cancer: an updateen
dc.typeText-
dc.type.publicationtypearticle-
dcterms.accessRightsopen access-
eldorado.dnb.zdberstkatid2132560-1-
Appears in Collections:Review Articles

Files in This Item:
File Description SizeFormat 
Crook_26082014_proof.pdfDNB148.54 kBAdobe PDFView/Open


This item is protected by original copyright



This item is protected by original copyright rightsstatements.org